Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
A phase 2 trial of IO102-IO103 in melanoma, run by IO Biotech, now recruiting.
Overview
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors is a phase 2 interventional study registered as NCT05280314 by IO Biotech, with 60 participants planned, started 2023-12-21 and due to reach its primary completion in 2025-04-30. Interventions recorded: IO102-IO103, Pembrolizumab KEYTRUDA®. Conditions listed: Melanoma, Squamous Cell Carcinoma of Head and Neck. No results are recorded here; the registry entry is the source.
Setting
Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
Phase
Phase 2
Sponsor
IO Biotech
Registry
Enrolled
60